Lactate transport inhibition therapeutically reprograms fibroblast metabolism in experimental pulmonary fibrosis.


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
28 Apr 2024
Historique:
medline: 7 5 2024
pubmed: 7 5 2024
entrez: 7 5 2024
Statut: epublish

Résumé

Myofibroblast differentiation, essential for driving extracellular matrix synthesis in pulmonary fibrosis, requires increased glycolysis. While glycolytic cells must export lactate, the contributions of lactate transporters to myofibroblast differentiation are unknown. In this study, we investigated how MCT1 and MCT4, key lactate transporters, influence myofibroblast differentiation and experimental pulmonary fibrosis. Our findings reveal that inhibiting MCT1 or MCT4 reduces TGFβ-stimulated pulmonary myofibroblast differentiation Small molecule inhibitors of lactate transporters, including the novel MCT4 inhibitor VB253, reprogram fibroblast metabolism to prevent myofibroblast differentiation and decrease bleomycin-induced pulmonary fibrosis.

Identifiants

pubmed: 38712233
doi: 10.1101/2024.04.25.591150
pmc: PMC11071479
pii:
doi:

Types de publication

Preprint

Langues

eng

Auteurs

Classifications MeSH